Results of Operations and Financial Condition - Form 8-K

Item 2.02 Results of Operations and Financial Condition.

On January 8, 2024, IGM Biosciences, Inc. (the "Company") announced its preliminary, unaudited cash and investments balance as of December 31, 2023. Based upon preliminary estimates and information available to the Company as of the date of this Form 8-K, as of December 31, 2023, the Company had approximately $337.7 million in cash and investments.

The information furnished under this Item 2.02 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our preliminary estimates of cash and investments as of December 31, 2023. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include the risk that our actual cash and investments balance as of December 31, 2023 may differ from the estimates presented in this Current Report on Form 8-K; as well as the other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements.